Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: A randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension

Clinical Drug Investigation

Volumn 32, Issue 1, 2012, Pages 29-39

  Na, Yanqun ^a   Ye, Zhangqun ^b   Zhang, Shanzhong ^c  

^a Peking University Hospital and Institute   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c GLAXOSMITHKLINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GYNECOMASTIA; HAIR GROWTH; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT DURATION; MIDDLE AGED; PROSTATIC HYPERPLASIA;

5-ALPHA REDUCTASE INHIBITORS; ADULT; AGED; AZASTEROIDS; CHINA; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSTATIC HYPERPLASIA; DUTASTERIDE;

EID: 82555173129     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11593750-000000000-00000     Document Type: Article

References (21)

1. BushmanW. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009 Nov; 36 (4): 403-15
2. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008 Dec; 20 Suppl. 3: S11-8
3. Guo Y, Shi J, Hu M, et al. Construction and validation of a short-form quality-of-life scale for Chinese patients with benign prostatic hyperplasia. Health Qual Life Outcomes 2009; 7: 24
4. Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008 Jul; 62 (7): 1076-86 (Pubitemid 351793595)
5. Djavan B, Fong YK, Harik M, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004 Dec; 64 (6): 1144-8 (Pubitemid 39647056)
6. Hong SK, Lee ST, Jeong SJ, et al. Chronic kidney disease amongmen with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2010May; 105 (10): 1424-8
7. OConnor RC, Laven BA, Bales GT, et al. Nonsurgical management of benign prostatic hyperplasia in men with bladder calculi. Urology 2002 Aug; 60 (2): 288-91 (Pubitemid 34831774)
8. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 2008; 10 (1): 14-25
9. Hashim H, Abrams P. Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs 2010 Jun; 15 (2): 159-74
10. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004 Oct; 172 (4 Pt 1): 1399-403 (Pubitemid 39249729)
11. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alphareductase inhibitor. J Clin Endocrinol Metab 2004 May; 89 (5): 2179-84 (Pubitemid 38619850)
12. Choi YH, Cho SY, Cho IR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride. Korean J Urol 2010 Oct; 51 (10): 704-8
13. Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged 65 years. Am J Manag Care 2008 May; 14 (5 Suppl. 2): S154-9
14. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 Apr; 63 (4): 709-15 (Pubitemid 38479415)
15. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep; 60 (3): 434-41 (Pubitemid 35292169)
16. Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009 Sep; 16 (9): 745-50
17. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011 Jan; 95 (1): 87-100
18. Mariappan P, Turner KJ, Sothilingam S, et al. Nocturia, nocturia indices and variables from frequency-volume charts are significantly different in Asian and Caucasian men with lower urinary tract symptoms: a prospective comparison study. BJU Int 2007 Aug; 100 (2): 332-6 (Pubitemid 47036579)
19. Coyne KS, Kaplan SA, Chapple CR, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 2009 Apr; 103 Suppl. 3: 24-32
20. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int 2002 Jul; 90 (2): 162-73 (Pubitemid 34779587)
21. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011 Jan; 185 (1): 126-31